Produção Nacional
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
2019; Instituto Israelita de Ensino e Pesquisa Albert Einstein; Volume: 17; Issue: 2 Linguagem: Inglês
10.31744/einstein_journal/2019gs4414
ISSN2317-6385
AutoresPedro Nazareth Aguiar, Pui San Tan, Sarah Simko, Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro del Giglio, Gilberto Lopes,
Tópico(s)Statistical Methods in Clinical Trials
ResumoObjective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted [...]
Referência(s)